BASEL MEDICAL GROUP LTD (BMGL) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BMGL • VGG0864B1031

0.651 USD
+0.04 (+6.42%)
At close: Feb 6, 2026
0.6506 USD
0 (-0.06%)
After Hours: 2/6/2026, 8:19:58 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall BMGL gets a fundamental rating of 2 out of 10. We evaluated BMGL against 102 industry peers in the Health Care Providers & Services industry. BMGL may be in some trouble as it scores bad on both profitability and health. BMGL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year BMGL has reported negative net income.
  • BMGL had a negative operating cash flow in the past year.
BMGL Yearly Net Income VS EBIT VS OCF VS FCFBMGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 0 -5M -10M

1.2 Ratios

  • BMGL has a Return On Assets of -73.60%. This is amonst the worse of the industry: BMGL underperforms 89.22% of its industry peers.
  • BMGL has a worse Return On Equity (-255.19%) than 78.43% of its industry peers.
  • BMGL's Return On Invested Capital of 10.26% is amongst the best of the industry. BMGL outperforms 81.37% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BMGL is significantly above the industry average of 9.16%.
  • The 3 year average ROIC (22.16%) for BMGL is well above the current ROIC(10.26%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -73.6%
ROE -255.19%
ROIC 10.26%
ROA(3y)-15.8%
ROA(5y)N/A
ROE(3y)-62.92%
ROE(5y)N/A
ROIC(3y)22.16%
ROIC(5y)N/A
BMGL Yearly ROA, ROE, ROICBMGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 0 -100 -200

1.3 Margins

  • BMGL has a better Operating Margin (4.53%) than 62.75% of its industry peers.
  • In the last couple of years the Operating Margin of BMGL has declined.
  • BMGL does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 4.53%
PM (TTM) N/A
GM N/A
OM growth 3Y-61.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMGL Yearly Profit, Operating, Gross MarginsBMGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • BMGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for BMGL has been increased compared to 1 year ago.
  • The debt/assets ratio for BMGL has been reduced compared to a year ago.
BMGL Yearly Shares OutstandingBMGL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 5M 10M 15M
BMGL Yearly Total Debt VS Total AssetsBMGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

  • BMGL has an Altman-Z score of -0.33. This is a bad value and indicates that BMGL is not financially healthy and even has some risk of bankruptcy.
  • BMGL has a Altman-Z score of -0.33. This is in the lower half of the industry: BMGL underperforms 79.41% of its industry peers.
  • A Debt/Equity ratio of 0.28 indicates that BMGL is not too dependend on debt financing.
  • BMGL has a Debt to Equity ratio of 0.28. This is in the better half of the industry: BMGL outperforms 67.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z -0.33
ROIC/WACC0.92
WACC11.15%
BMGL Yearly LT Debt VS Equity VS FCFBMGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 2M -2M 4M -4M 6M

2.3 Liquidity

  • A Current Ratio of 1.23 indicates that BMGL should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.23, BMGL is in line with its industry, outperforming 46.08% of the companies in the same industry.
  • BMGL has a Quick Ratio of 1.19. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
  • BMGL has a Quick ratio (1.19) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.19
BMGL Yearly Current Assets VS Current LiabilitesBMGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for BMGL have decreased strongly by -458.69% in the last year.
  • BMGL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.02%.
  • The Revenue has been growing slightly by 2.03% on average over the past years.
EPS 1Y (TTM)-458.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-673.02%
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMGL Yearly Revenue VS EstimatesBMGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • BMGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMGL Price Earnings VS Forward Price EarningsBMGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • 99.02% of the companies in the same industry are more expensive than BMGL, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.2
BMGL Per share dataBMGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BMGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BASEL MEDICAL GROUP LTD

NASDAQ:BMGL (2/6/2026, 8:19:58 PM)

After market: 0.6506 0 (-0.06%)

0.651

+0.04 (+6.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners1.58%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap12.23M
Revenue(TTM)16.35M
Net Income(TTM)-12.40M
AnalystsN/A
Price TargetN/A
Short Float %1.6%
Short Ratio1.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.95
P/FCF N/A
P/OCF N/A
P/B 3.2
P/tB 3.2
EV/EBITDA 1.2
EPS(TTM)-0.52
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.68
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.6%
ROE -255.19%
ROCE 12.02%
ROIC 10.26%
ROICexc N/A
ROICexgc N/A
OM 4.53%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-15.8%
ROA(5y)N/A
ROE(3y)-62.92%
ROE(5y)N/A
ROIC(3y)22.16%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)33.64%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-61.23%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA 0.71
Cap/Depr 4.64%
Cap/Sales 0.34%
Interest Coverage 1.14
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.19
Altman-Z -0.33
F-Score3
WACC11.15%
ROIC/WACC0.92
Cap/Depr(3y)2.42%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.21%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-458.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-673.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.02%
Revenue growth 3Y2.03%
Revenue growth 5YN/A
Sales Q2Q%12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-90.22%
EBIT growth 3Y-60.44%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-275.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-273.12%
OCF growth 3YN/A
OCF growth 5YN/A

BASEL MEDICAL GROUP LTD / BMGL FAQ

What is the fundamental rating for BMGL stock?

ChartMill assigns a fundamental rating of 2 / 10 to BMGL.


What is the valuation status for BMGL stock?

ChartMill assigns a valuation rating of 1 / 10 to BASEL MEDICAL GROUP LTD (BMGL). This can be considered as Overvalued.


What is the profitability of BMGL stock?

BASEL MEDICAL GROUP LTD (BMGL) has a profitability rating of 3 / 10.